Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars
Firm Concedes That Adoption Of Adalimumab Rivals ‘Has Not Reached Anticipated Potential’
Boehringer Ingelheim’s decision to cut sales staff for its Cyltezo US biosimilar rival to Humira not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the struggles for Humira biosimilars more widely.
